Public scandal - People with Alzheimer’s disease being denied essential drug treatments

People with Alzheimer’s disease will be denied essential drug treatments as part of a new cost-cutting exercise being considered by East Sussex County Healthcare Trust.

The trust is threatening to stop assessing people with Alzheimer’s disease for treatment with anticholinesterase drugs. These drugs are known to have benefited many people with the disease, as they can help relieve the symptoms of their condition.

The trust says it may be forced to introduce the controversial measures to make up for insufficient funding. Under the proposed three-month moratorium people living in care homes would be denied dementia drugs ‘unless permitted within resources’. Priority will be given to those living in their own homes.

David Sutcliffe, chairman of the Eastbourne and district branch of the Alzheimer’s Society, cannot understand why the trust finds it acceptable to limit treatment for people with dementia in this way.

"It is wrong to assume that people with Alzheimer’s disease in care homes can’t benefit from these drug treatments. There is no good financial or moral reason why they should not receive equal access to healthcare. It appears that the trust has picked on one of the most marginalised groups in our society; people who are often too physically and mentally frail to speak out for themselves."

The Alzheimer's Society believes that this is a public scandal, and has written to the Department of Health and the National Institute for Clinical Excellence to ask what action will be taken to end this unacceptable state of affairs.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options